SWTX240816C40000
- 1.85
- -1.15-38.33%
SpringWorks Therapeutics Newsroom
Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
SpringWorks Therapeutics, Inc. (SWTX Quick QuoteSWTX - Free Report) announced that it has completed the submission of a new drug application (“NDA”) for its investigational MEK inhibitor, mirdametinib, being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients.
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Issues a Buy Rating on Springworks Therapeutics (SWTX)
Sector Update: Health Care Stocks Mixed Premarket Monday
Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics
Sector Update: Health Care
Health care stocks were flat to higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was inactive and the iShares Biotechnology ETF (IBB) was up 0.4% recently. SpringWorks Therapeu
Express News | SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
Express News | SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults With Nf1-Pn
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen analyst Yaron Werber maintains $SpringWorks Therapeutics(SWTX.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate of 57.8%
Express News | SpringWorks Therapeutics Inc : JP Morgan Cuts Target Price to $64 From $77
GSK, SpringWorks End Collaboration Agreement
Express News | SpringWorks Therapeutics Inc Says Termination Of License Deal Does Not Trigger Any Payment Obligations On Part Of Co/any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Says Termination Does Not Affect Co's Rights To Continue Developing Or Commercializing Its Products Or Product Candidates; Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination of License Deal Does Not Trigger Any Payment Obligations on Part of Co/Any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Inc - Co Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination Does Not Affect Co's Rights to Continue Developing or Commercializing Its Products or Product Candidates
Express News | SpringWorks Therapeutics:Deal Termination Between Co & Glaxosmithkline Intellectual Property Development Effective 180 Days After Notice Receipt
Express News | SpringWorks Therapeutics:Got Notice of Termination of Amended & Restated Collaboration and License Agreement, Dated Sept 6, 2022, Between Co & GSK
Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
SpringWorks Therapeutics(SWTX.US) Officer Sells US$801.37K in Common Stock
$SpringWorks Therapeutics(SWTX.US)$ Officer Edris Badreddin sold 20,000 shares of common stock on Jun 3, 2024 at an average price of $40.0686 for a total value of $801.37K.Source: Announcement What is